The Jinling Cohort
A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population
Nanjing Shihejiyin Technology, Inc.
15,000 participants
Jun 15, 2022
OBSERVATIONAL
Conditions
Summary
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
Eligibility
Inclusion Criteria1
- 、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent
Exclusion Criteria7
- Pregnant women;
- Individuals who have history of cancer or current diagnosis of cancer;
- Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
- Individulas who have blood transfusion within 30 days prior to the blood draw;
- Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;
- Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;
- Individuals who will not be able to comply with the protocol procedures judged by researchers
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06011694